2,5-Dimethoxy-4-ethylamphetamine

Identification

Name
2,5-Dimethoxy-4-ethylamphetamine
Accession Number
DB01467
Type
Small Molecule
Groups
Experimental, Illicit
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
9SK6K682UL
CAS number
22004-32-6
Weight
Average: 223.3113
Monoisotopic: 223.157228921
Chemical Formula
C13H21NO2
InChI Key
HXJKWPGVENNMCC-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO2/c1-5-10-7-13(16-4)11(6-9(2)14)8-12(10)15-3/h7-9H,5-6,14H2,1-4H3
IUPAC Name
1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
SMILES
CCC1=CC(OC)=C(CC(C)N)C=C1OC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
AceprometazineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
AcetophenazineAcetophenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
Acrivastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Acrivastine.
Alcaftadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Alcaftadine.
AlfentanilThe risk or severity of serotonin syndrome can be increased when Alfentanil is combined with 2,5-Dimethoxy-4-ethylamphetamine.
Alimemazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Alimemazine.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
27402
PubChem Substance
46504746
ChemSpider
25499
BindingDB
81965
ChEMBL
CHEMBL8224
Wikipedia
2,5-Dimethoxy-4-ethylamphetamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.81HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.413 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity66.27 m3·mol-1ChemAxon
Polarizability26.07 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9187
Caco-2 permeable+0.7659
P-glycoprotein substrateNon-substrate0.6693
P-glycoprotein inhibitor INon-inhibitor0.7698
P-glycoprotein inhibitor IINon-inhibitor0.9743
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.857
CYP450 2D6 substrateSubstrate0.7859
CYP450 3A4 substrateNon-substrate0.5212
CYP450 1A2 substrateInhibitor0.7137
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorInhibitor0.7927
CYP450 2C19 inhibitorNon-inhibitor0.8757
CYP450 3A4 inhibitorNon-inhibitor0.9168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6931
Ames testNon AMES toxic0.6594
CarcinogenicityNon-carcinogens0.7386
BiodegradationNot ready biodegradable0.8571
Rat acute toxicity3.0939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9017
hERG inhibition (predictor II)Non-inhibitor0.6282
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Dimethoxybenzene / P-dimethoxybenzene / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Aralkylamine / Alkyl aryl ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:09 / Updated on October 01, 2018 13:04